Patents Examined by Sean R Donohue
  • Patent number: 10765763
    Abstract: A radioligand for labeling myelin includes a fluorescent trans-stilbene derivative.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 8, 2020
    Inventors: Yanming Wang, Chunying Wu
  • Patent number: 10753941
    Abstract: The development of fluorescent bioprobes comprising organic fluorescent compounds that exhibit aggregation induced emission (AIE) properties, methods of producing the same, and their practical applications for in vitro and in vivo bioimaging.
    Type: Grant
    Filed: September 3, 2012
    Date of Patent: August 25, 2020
    Assignees: The Hong Kong University of Science and Technology, National University of Singapore
    Inventors: Benzhong Tang, Wei Qin, Jianzhao Liu, Sijie Chen, Tsz Kin Kwok, Bin Liu, Kai Li, Dan Ding, Haibin Shi, Jun Long Geng, Jingzhi Sun, Anjun Qin, Qiuli Zhao
  • Patent number: 10716869
    Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 21, 2020
    Assignee: Oncodesign SA
    Inventors: Jan Marie Cyriel Jozef Hoflack, Cyril Berthet, Petra Marcella Françoise Blom, Johnny Vercouillie, Caroline Robic, Sarah Catoen, Gilles Voit, Jean-Bernard Deloye
  • Patent number: 10710968
    Abstract: Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: July 14, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Eyal Yosef Mishani, Ofer Shamni, Galith Rachel Abourbeh-Gofrit
  • Patent number: 10709798
    Abstract: A composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: July 14, 2020
    Inventors: Sondre Nilsen, Srinath Balaji Aralikatti Prahladachar Balaji, Umamaheshwar P. Mokkapati, Afsal Mohammed Kadavilpparampu Mohamed
  • Patent number: 10696692
    Abstract: The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: June 30, 2020
    Inventors: Kenneth W Bair, Timm R Baumeister, Alexandre J Buckmelter, Karl H Clodfelter, Peter Dragovich, Francis Gosselin, Janet Gunzner-Toste, Bingsong Han, Jian Lin, Xiongcai Liu, Dominic J Reynolds, Chase C Smith, Zhongguo Wang, Mark Zak, Yamin Zhang, Guiling Zhao, Xiaozhang Zheng, Po-Wai Yuen
  • Patent number: 10675364
    Abstract: The present disclosure encompasses embodiments of a novel near-infrared-emitting molecular fluorophore and probes incorporating said fluorophore advantageous for in vitro and in vivo research studies. The fluorophore is robust, photostable, and possesses functionalities for easy bioorthogonal conjugation (e.g., click chemistry, hydrazone formation, Diels Alder, Staudinger ligation, etc.). It is biocompatible and emits at 711 nm in aqueous conditions. These fluorophores may be used to fluorescently tag biological molecules or structures of interest, or used as optical reporters (i.e., activatable molecular probes, fluorescent dyes) for specific biomarkers/analytes as they can be switched from “off” to “on.” This fluorophore is useful for cellular assays and preclinical small animal imaging as the near-infrared emission is highly penetrating, and the photophysical properties are outstanding. As such, the properties of this class of fluorophores could easily be translated for use in clinical applications.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 9, 2020
    Inventors: Kenneth Hettie, Jessica Klockow, Timothy Glass, Frederick T. Chin
  • Patent number: 10675365
    Abstract: The present invention relates to a curcumin derivative, a method for producing same, and a photo-acoustic imaging agent comprising the curcumin derivative for detecting beta-amyloid plaque. The curcumin derivative, expressed by chemical formula 1, according to the present invention exhibits superb selective bonding with beta-amyloid, thereby allowing beta-amyloid to be detected by means of an optical or photo-acoustic imaging methods, and, particularly, the curcumin derivative can highly effectively detect photo-acoustic signals with almost no noise by reacting to irradiation of light having a particular wavelength range, and thus can be useful as a composition for detecting beta-amyloid and for diagnosing diseases caused by excessive production of beta-amyloid.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 9, 2020
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Yong-Dae Park, Jung-Joon Min, Seung-Dae Yang, Min-Goo Hur, Seung-Jin Jung, Yeong-Jin Hong, Seung-Hwan Park
  • Patent number: 10660976
    Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 26, 2020
    Assignee: Washington University
    Inventor: Vijay Sharma
  • Patent number: 10653805
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 19, 2020
    Assignee: The General Hospital Corporation
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Patent number: 10640457
    Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: May 5, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Yan Feng, Mauro Fa, Ottavio Arancio, Shixian Deng, Donald W. Landry, Yitshak Francis
  • Patent number: 10633404
    Abstract: This disclosure relates to compositions comprising substituted iminodiacetic acid ligands and metal tricarbonyl complexes containing the ligands and derivatives thereof. In certain embodiments, the metal tricarbonyl complexes are used as radioisotope tracers such as renal tracers. In certain embodiments, the metal complexes comprise 99mTc or Re. In certain embodiments, the ligands are substituted with a fluorine, a fluorine-18 (F18) radioisotope, or other radionuclide.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: April 28, 2020
    Assignee: Emory University
    Inventors: Jeffrey Klenc, Malgorzata Lipowska, Andrew Taylor
  • Patent number: 10604516
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 31, 2020
    Assignee: National Institutes for Quantum and Radiological Science and Technology
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 10604523
    Abstract: The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET).
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: March 31, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Peter Jacobus Johannes Antonius Buijnsters, Andrés Avelino Trabanco-Suárez, Meri De Angelis, Greta Constantia Peter Vanhoof, Jérôme Emile Georges Guillemont, Frederik Jan Rita Rombouts, Maarten Vliegen, Guy Maurits R. Bormans, Sofie Jeanne Leopoldine Celen
  • Patent number: 10568978
    Abstract: The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: February 25, 2020
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, James F. Castner
  • Patent number: 10561748
    Abstract: The present invention is directed to a novel compound of Formula 1 wherein the radiolabeled compound of Formula 1 is capable of being used as a radiotracer in PET imaging of a targeted localized tissue and targeted radionuclide therapy of one or more conditions that may be regulated or normalized via inhibition of transporter such as Pgp, BCRP or MRP I. The novel compounds of Formula 1 can also be used as substrates for binding with one or more ABC transporters. In particular, the present invention aids in diagnosis and therapeutic treatment of MDR disorders in all forms of cancers and neurological disorders of the central nervous system. The present invention further provides methods of preparation of compounds of Formula 1 and novel intermediates used in the preparation of compounds of Formula 1.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: February 18, 2020
    Inventor: Divya Maheshwari
  • Patent number: 10548996
    Abstract: Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: February 4, 2020
    Inventors: Abdel Kareem Azab, Pilar de la Puente, Feda Azab
  • Patent number: 10538486
    Abstract: The present invention relates to a hydroxamic acid-based contrast agent containing an isotope of fluorine, which comprises a compound having a structure of Formula (III): wherein R1 represents radioactive fluorine-18 (18F) or isotope fluorine-19 (19F), and R2 represents hydroxyamine —(NH)OH. The hydroxamic acid-based contrast agent containing an isotope of fluorine provided in the present invention has the capability of selectively inhibiting histone deacetylase (HDAC) subtypes 8/6/3, and specifically targets to the focus of spinocerebellar ataxia with over-activation of HDAC. By labeling with the radioisotope fluorine-18, a positron emission tomography (PET) image is obtained with the hydroxamic acid-based contrast agent containing radioisotope fluorine-18, whereby spinocerebellar ataxia is effectively detected.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: January 21, 2020
    Inventors: Mei-Hui Wang, Chia-Yu Hu, Mao-Chi Weng, Jyun-Hong Chen, Chun-Hung Yang, Hung-Man Yu
  • Patent number: 10517965
    Abstract: This present application relates to fluorescent tetrazine-containing compounds consisting of a single pi-system. For example, a compound of Formula (I): or a salt thereof, wherein: F is a fluorophore, L is a conjugated linker, and Tz is a substituted or unsubstituted tetrazine; wherein the linker bridges the Tz and F moieties in a single conjugated pi-system. Also provided herein are methods of using the compounds provided herein for biomedical imaging.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: December 31, 2019
    Assignee: The General Hospital Corporation
    Inventors: Labros Meimetis, Jonathan Carlson, Ralph Weissleder
  • Patent number: 10463753
    Abstract: Provided herein are monoacylglycerol lipase (MGLL) occupancy probes comprising a MGLL inhibitor containing a positron emission tomography (PET) tracer radionuclide. Also provided are methods of assessing MGLL enzyme occupancy of a MGLL inhibitor using the radiolabeled occupancy probes described herein.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 5, 2019
    Inventors: Cheryl A. Grice, Todd K. Jones, Justin S. Cisar, Iain Peter Fraser